ASH 2022 | SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHL
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the ongoing SUNMO Phase III trial which is evaluating the efficacy and safety of mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL) in comparison with the standard of care regimen rituximab, gemcitabine and oxaliplatin (R-GemOx) (NCT05171647). Dr Westin anticipates encouraging results from the novel targeted therapy being trialed in comparison to R-GemOx. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
ADC Therapeutics: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Iksuda: Consultancy; MonteRosa: Consultancy; Merck: Consultancy; Abbvie/GenMab: Consultancy; Calithera: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; SeaGen: Consultancy.
